About Alaxia

ALX 009 / Cystic Fibrosis Foundation / Pipeline :
A Phase 1 study to test the safety and tolerability of ALX-009 is underway.

Alaxia is a French private biotech company developing therapeutic solutions for respiratory diseases based on its proprietary peroxidase platform. The most advanced drug candidate, ALX-009, is an antimicrobial innovative compound aiming at treating cystic fibrosis, including the most resistant bacterial strains.

ALX-009 - Tests